On December 7, the National Development and Reform Commission legally imposed administrative penalties on the medical equipment giant Medtronic (Shanghai) Management Co., Ltd. and its counterparts to reach and implement a monopoly agreement on the price of medical devices in the fields of cardiovascular, reductive therapy and diabetes. The fine was 118.5 million yuan. This is the first medical product price monopoly case issued by China, completely breaking the long-term position of foreign-owned medical equipment in China. In addition, what are the hot spots in the medical industry in the near future? The editor of OFweek Medical Network will take you to review it.
News review
China's first anti-monopoly investigation of medical equipment was placed in Medtronic: fined 118 million
Recently, the National Development and Reform Commission has imposed administrative penalties on the act of Medtronic (Shanghai) Management Co., Ltd. and its counterparts in dealing with and implementing the monopoly agreement on the price of medical devices in the fields of cardiovascular, reductive therapy and diabetes, with a fine of 118.5 million yuan. [ Original reading ]
.jpg)
American Cell Magazine: Artemisinin of the Tu Yu team can cure diabetes
Recently, the artemisinin drug developed by our pharmacist Tu Yu and her team is still the world's leading antimalarial drug, which has saved millions of lives. A breakthrough study published online in the US Cell on December 1st showed that the drug may also save hundreds of millions of people with diabetes. Scientists from institutions such as the CeMM Center for Molecular Medicine in the Austrian Academy of Sciences, using a specially designed, fully automated analysis, have examined the effects of a large number of approved drugs on artificially cultured alpha cells. As a result, it was surprisingly found that artemisinin can cause the glucagon-producing alpha cells to "transform" to produce beta cells of insulin. [ Original reading ]
.jpg)
Abbott officially cancels the acquisition of US Airil
In February 2016, Abbott’s announcement of a $5.8 billion acquisition of US Airil sparked heated discussions in the industry. However, the two companies continued to fluctuate. First, Abbott acquired St. Jude for $25 billion in April, and then continued to have Abbott and A. Unpleasant news came out, and a series of rumors of cooperation problems. Various conjectures were settled this week. On Wednesday (December 7th), Abbott officially announced the cancellation of its decision to acquire US Airil. Fortune subsequently made a report explaining this. Today, I will take a look at this report with the readers and review the twists and turns. [ Original reading ]
.jpg)
Berry and Kang back shell Tianxing instrument latest progress: market assessment price of 4.3 billion yuan
At the end of August, after the news that Berry and Kang’s “Tianxing Instrument†was listed, finally progressed. On the evening of December 4th, Tianxing Instrument released the “Evaluation Report on the Shareholders' Equity of Beijing Berry and Kang Biotech Co., Ltd., which is proposed to be involved in major asset restructuring†and “Shen Wan Hongyuan Securities Underwriting Sponsorship Limited Liability†The Company's Financial Adviser Opinions on the Company's Detailed Statement of Changes in Equity and the Independent Financial Adviser Report of CITIC Jiantou Securities Co., Ltd. on the Company's Issue of Share Purchase Assets and Major Asset Sale and Related Transactions. [ Original reading ]
.jpg)
Best Reusable Ffp2 Mask Uk,Reusable Ffp2 Mask Uk,Ffp2 Mask Vs N95,Ffp2 Mask Vs Kn95
Zhejiang Lanhine Medical Products Ltd. , https://www.lanheyiliao.com